Hemangiosarcoma in Dogs: Breeds, Emergency Signs, and Care

Hemangiosarcoma is an aggressive cancer of blood vessel cells that disproportionately strikes dogs, particularly large breeds like Golden Retrievers and German Shepherds. It accounts for roughly a fifth of all soft tissue sarcomas in dogs and tends to grow silently inside the spleen, heart, or liver before announcing itself through internal bleeding or collapse. The disease is devastating in part because it is rarely caught early, and even with treatment, survival times are measured in months rather than years. But the picture is not entirely hopeless, and understanding what this cancer does, how it behaves in different locations, and what treatment options exist can help owners make informed decisions during an incredibly stressful time.

What Hemangiosarcoma Actually Is

Hemangiosarcoma originates from endothelial cells, the cells that line the inside of blood vessels. Because blood vessels exist everywhere in the body, this cancer can theoretically develop almost anywhere, but it has a strong preference for certain organs. The spleen is the most common site, followed by the heart’s right atrium and the liver. When it arises in the skin or just beneath it, the disease behaves quite differently, and the outlook can be considerably better.

One reason the cancer is so dangerous internally is that the tumors form fragile, blood-filled cavities. These cavities can rupture without warning, causing sudden and sometimes life-threatening internal hemorrhage. Many owners first learn their dog has hemangiosarcoma when the dog collapses and is rushed to an emergency clinic with a belly full of blood.

Research into the tumor’s biology has revealed that not all hemangiosarcomas are the same at the molecular level. Gene expression profiling has identified at least three functional subtypes. One subtype is dominated by blood vessel growth and formation signals. A second is driven by immune and inflammatory pathways. A third is characterized by fat and cholesterol metabolism genes.

1PubMed Central. Identification of Three Molecular and Functional Subtypes in Canine Hemangiosarcoma through Gene Expression Profiling and Progenitor Cell Characterization These subtypes may explain why some tumors behave more aggressively than others and why individual dogs respond differently to the same treatment.

Breeds at Risk and the Genetics Behind It

Certain breeds carry a significantly higher risk of developing hemangiosarcoma, and Golden Retrievers sit at the top of nearly every list. German Shepherds, Labrador Retrievers, Portuguese Water Dogs, and Boxers also appear frequently in veterinary oncology studies. The breed clustering is not coincidental. Heritable genetic factors play a real role, and researchers have started to untangle what those factors look like at the DNA level.

A large genomic study of canine hemangiosarcoma found that the most frequently mutated gene was TP53, a well-known tumor suppressor, altered in about 60% of cases. Two genes in the PI3K signaling pathway, PIK3CA and PIK3R1, were also commonly mutated. Other recurring changes included deletions of the tumor-suppressor region CDKN2A/B and gains in genes involved in blood vessel growth like VEGFA and KDR.

2PubMed Central. Comparative genomics reveals shared mutational landscape in canine hemangiosarcoma and human angiosarcoma

Interestingly, Golden Retrievers appear to develop a molecularly distinct version of the disease. When researchers profiled tumors across five high-risk breeds, the overall pattern of DNA copy number changes was broadly similar, but Golden Retrievers showed about half the rate of VEGFA gene gains compared to other breeds.

3PubMed Central. Genomic profiling reveals extensive heterogeneity in somatic DNA copy number aberrations of canine hemangiosarcoma A separate gene expression study found a five-gene signature that reliably separated Golden Retriever hemangiosarcomas from those in other breeds, with differences in immune-related and blood vessel growth genes. One particularly striking finding was that a receptor called VEGFR1, which in many cancers acts as a decoy that dampens growth signals, appeared to function as an active growth inhibitor specifically in Golden Retriever tumors.

4PLOS ONE. Gene Expression Profiles of Sporadic Canine Hemangiosarcoma Are Uniquely Associated with Breed

What this means in practical terms is that hemangiosarcoma is not a single uniform disease. Breed background influences the molecular character of the tumor, which may eventually guide treatment choices as veterinary oncology moves toward more personalized approaches.

The Emergency Presentation

The classic hemangiosarcoma emergency goes something like this: a seemingly healthy large-breed dog, often middle-aged or older, suddenly becomes weak, pale, or collapses. At the emergency clinic, an ultrasound reveals fluid in the abdomen, which turns out to be blood from a ruptured splenic mass. The owner, who had no idea anything was wrong an hour ago, is now facing a life-or-death decision about emergency surgery.

This scenario is terrifying, but there is an important detail that gets lost in the panic. Not every ruptured splenic mass is hemangiosarcoma. Studies have shown that 40 to 50% of ruptured splenic tumors turn out to be benign, and more than 96% of these large-breed dogs walk out of the hospital less than 40 hours after surgery.

5Ethos Discovery. Hemangiosarcoma in Dogs That statistic matters enormously because some owners are advised to euthanize immediately without pursuing surgery, potentially losing a dog that had a benign tumor and could have recovered fully. Emergency splenectomy is a well-established procedure, and stabilizing the dog with blood transfusions and fluids before surgery is standard practice.

The catch, of course, is that you cannot tell whether a splenic mass is benign or malignant until it has been surgically removed and examined by a pathologist. Fine-needle aspirates of splenic masses are often inconclusive because hemangiosarcoma cells do not exfoliate well into fluid samples, and the risk of puncturing a blood-filled mass makes aggressive biopsy attempts dangerous. So the decision to operate is usually made without a definitive diagnosis, on the reasonable bet that the surgery itself is both therapeutic and diagnostic.

Where Hemangiosarcoma Develops

The spleen is the most common primary site, but hemangiosarcoma’s reach extends well beyond it. The right atrium of the heart is the second most common visceral location, and cardiac hemangiosarcoma is particularly cruel because it can cause pericardial effusion, where fluid accumulates in the sac around the heart and compresses it, leading to weakness and collapse. Diagnosis often involves echocardiography: in one reported case, a Golden Retriever with a right atrial mass benefited from three-dimensional echocardiography that helped surgeons determine the tumor was not infiltrating the heart wall, allowing them to proceed with surgical removal.

6PubMed Central. Real-time three-dimensional echocardiographic study of a cardiac hemangiosarcoma in a dog

The liver is another frequent site, both as a primary tumor and as a destination for metastatic spread. In a study of dogs with splenic hemangiosarcoma, about 42% already had detectable spread at diagnosis. The liver was the most common metastatic site, found in 28% of all dogs in the study, followed by the peritoneum, lungs, and musculature.

7Journal of Veterinary Internal Medicine. Frequency, distribution, and prognostic impact of metastatic site in dogs with splenic hemangiosarcoma

Less commonly, hemangiosarcoma can appear in limb bones, where it needs to be distinguished from another bone tumor called telangiectatic osteosarcoma, which looks similar on imaging. In a study comparing the two, about 78% of appendicular hemangiosarcomas occurred in the hind limbs, with a preference for the tibia.

8PubMed. Primary appendicular hemangiosarcoma and telangiectatic osteosarcoma in 70 dogs

Skin and Subcutaneous Forms

Hemangiosarcoma that develops in the skin, called dermal hemangiosarcoma, is a genuinely different beast from the visceral forms. Many dermal cases are linked to chronic sun exposure and tend to appear on lightly pigmented, sparsely haired skin on the belly or inner thighs of breeds like Whippets, Italian Greyhounds, and white-coated pit bull types. These sun-induced tumors carry a much better prognosis than their internal counterparts.

A study of 94 dogs with dermal hemangiosarcoma found a median survival time of nearly 1,000 days when treated with surgical excision. Dogs of predisposed breeds with tumors on the belly and evidence of solar damage on histopathology had the longest survivals. The trade-off is that local recurrence was common, occurring in 77% of cases. Dogs of non-predisposed breeds with invasive tumors were more likely to develop distant metastasis and had shorter survival.

9PubMed. Clinical outcome in 94 cases of dermal haemangiosarcoma in dogs treated with surgical excision: 1993-2007

The takeaway for owners of light-skinned dogs is straightforward: limiting sun exposure, especially during peak hours, and watching for dark, raised skin lesions on the belly or groin can catch these tumors earlier. And if your dog is diagnosed with dermal hemangiosarcoma, the conversation about prognosis should be very different from the one that follows a splenic hemangiosarcoma diagnosis.

Blood Clotting Problems

One of the most dangerous complications of hemangiosarcoma is a clotting disorder called disseminated intravascular coagulation, or DIC. In this condition, the body’s clotting system goes haywire, simultaneously forming tiny clots throughout the bloodstream while also using up the clotting factors needed to stop normal bleeding. The result is a paradox: excessive clotting and excessive bleeding at the same time.

In one study of dogs with hemangiosarcoma, half met criteria for DIC at the time they were first seen by a veterinarian. Low platelet counts were even more common, present in 75% of dogs. A quarter of the dogs in the study died as a direct result of these clotting abnormalities rather than from the cancer itself.

10PubMed. Hemostatic abnormalities in dogs with hemangiosarcoma This is why emergency management of a bleeding hemangiosarcoma often involves not just blood transfusions but also fresh frozen plasma to replace depleted clotting factors.

The tumor microenvironment itself contributes to these problems. Research has shown that hemangiosarcoma cells produce high levels of interleukin-8, an inflammatory signaling molecule whose gene signature in tumor tissue is directly associated with coagulation, fibrosis, and inflammation.

11PubMed Central. Interleukin-8 Promotes Canine Hemangiosarcoma Growth by Regulating the Tumor Microenvironment In other words, the cancer does not just grow; it actively reshapes its surroundings in ways that promote bleeding and further tumor progression.

Treatment and Realistic Expectations

For visceral hemangiosarcoma, treatment almost always starts with surgery. In splenic cases, that means an emergency or planned splenectomy. But surgery alone is not enough to control the disease for long. The median survival after splenectomy without follow-up chemotherapy is about 1.6 months.

12PubMed. Survival time of dogs with splenic hemangiosarcoma treated by splenectomy with or without adjuvant chemotherapy: 208 cases (2001-2012)

Adding chemotherapy, most commonly doxorubicin given intravenously every three weeks, extends that window meaningfully. In a study comparing surgery alone to surgery plus doxorubicin, dogs that received chemotherapy had a median survival of 274 days compared to 66 days for surgery alone.

13PubMed Central. Canine visceral hemangiosarcoma treated with surgery alone or surgery and doxorubicin: 37 cases (2005–2014) That is a substantial improvement, though it still means most dogs live less than a year even with the best conventional care. Doxorubicin has side effects including nausea, reduced appetite, and potential heart toxicity with repeated doses, but most dogs tolerate it reasonably well and maintain good quality of life during treatment.

For dogs that do not tolerate standard chemotherapy, metronomic protocols offer a gentler alternative. These use lower doses of oral drugs like chlorambucil given daily or every other day, aiming to slow tumor blood vessel growth rather than kill cancer cells directly. One case report documented a dog with stage III hemangiosarcoma that maintained excellent quality of life for 24 months on metronomic chlorambucil combined with complementary supplements, with no detectable metastasis during that period.

14PubMed Central. Hemangiosarcoma in a Dog: Unusual Presentation and Increased Survival Using a Complementary/Holistic Approach Combined with Metronomic Chemotherapy That outcome is exceptional and not typical, but it illustrates that some dogs do beat the odds, and lower-intensity treatment can occasionally produce surprisingly good results.

Confirming the Diagnosis

Pathologists confirm hemangiosarcoma by examining tissue under the microscope and staining for endothelial cell markers. Well-differentiated tumors form recognizable vascular channels and are relatively straightforward to identify. Poorly differentiated tumors are trickier. Some grow in solid sheets of cells that barely resemble blood vessels, and a few take on an epithelioid pattern that can be confused with carcinomas. Immunohistochemical staining for markers like CD31 and Factor VIII-related antigen helps resolve these difficult cases; in a study of 19 canine angiosarcomas, all but one tumor stained positive for at least one of these endothelial markers.

15PubMed. Canine angiosarcoma: cytologic, histologic, and immunohistochemical correlations

Staging, which determines how far the cancer has spread, typically involves chest X-rays and abdominal ultrasound, though CT scanning detects more metastatic sites. In the staging study cited earlier, dogs evaluated with CT were more likely to be classified as stage III (meaning distant spread was found) than those staged with X-rays and ultrasound alone, suggesting that conventional imaging misses some metastases.

16Journal of Veterinary Internal Medicine. Frequency, distribution, and prognostic impact of metastatic site in dogs with splenic hemangiosarcoma

Emerging Approaches

Research into new treatments is active and has produced some genuinely promising early results. One area of interest is combining standard chemotherapy with propranolol, a beta-blocker commonly used for heart conditions. Propranolol appears to interfere with blood vessel growth signals that hemangiosarcoma depends on. In a small study of five dogs with stage III disease, four showed clinical benefit from the combination, though median overall survival was still limited to about 141 days.

17PubMed Central. Efficacy and adverse events of anthracycline and propranolol combination in five dogs with stage 3 hemangiosarcoma

Immunotherapy is another frontier. A phase 2 clinical trial tested a peptide-based cancer vaccine given alongside standard surgery and chemotherapy. Dogs receiving the vaccine had a median overall survival of 276 days compared to 175 days in the standard-care group, and the one-year survival rate jumped from about 6% to nearly 36%.

18Cancers. A Phase 2, Single-Arm, Open-Label Clinical Trial on Adjuvant Peptide-Based Vaccination in Dogs with Aggressive Hemangiosarcoma Undergoing Surgery and Chemotherapy These numbers are encouraging, especially the one-year survival figure, but they come from a relatively small trial and need validation in larger studies before becoming standard practice.

Perhaps the most exciting long-term development is the possibility of catching hemangiosarcoma before it ruptures or spreads. Researchers have been developing liquid biopsy tests that analyze cell-free DNA circulating in the bloodstream. A recent study found that dogs with hemangiosarcoma had characteristic patterns in the size of their circulating DNA fragments and in gene copy number changes. A machine learning model trained on these patterns achieved strong accuracy in distinguishing dogs with hemangiosarcoma from healthy controls.

19PubMed Central. Early detection of canine hemangiosarcoma via cfDNA fragmentation and copy number alterations in liquid biopsies using machine learning A screening blood test for at-risk breeds could fundamentally change the disease by enabling surgical removal before tumors have ruptured or metastasized. That technology is not yet commercially validated, but the proof of concept is solid.

Why Veterinary Researchers Study This Cancer So Intensely

Hemangiosarcoma in dogs is not just a veterinary problem. It shares striking genomic similarities with human angiosarcoma, a rare and equally aggressive cancer of blood vessel cells. The same tumor suppressor and growth pathway mutations show up in both species, and the clinical behavior of the two diseases is remarkably parallel.

20PubMed Central. Comparative genomics reveals shared mutational landscape in canine hemangiosarcoma and human angiosarcoma

This makes dogs with naturally occurring hemangiosarcoma valuable as a translational model. Human angiosarcoma is so rare that large clinical trials are nearly impossible to run. Dogs get hemangiosarcoma at much higher rates, live with their owners in shared environments, develop the disease spontaneously rather than through artificial induction, and have compressed lifespans that allow researchers to observe treatment outcomes faster. Multiple research groups have pointed out that testing new therapies in client-owned dogs with hemangiosarcoma could inform human clinical trial design and identify effective treatments for both species.

21PLOS ONE. Molecular subtypes in canine hemangiosarcoma reveal similarities with human angiosarcoma Comparative genomic studies have extended this work to cats with hemangiosarcoma as well, finding that feline tumors also share key driver genes with the human disease.

22Disease Models & Mechanisms. Comparison of the oncogenomic landscape of canine and feline hemangiosarcoma shows novel parallels with human angiosarcoma

For dog owners, this means that the research dollars flowing into hemangiosarcoma are not just benefiting dogs. Every clinical trial that enrolls dogs with this cancer potentially advances treatment for a rare human disease that has few other paths toward progress. It is one of the clearest examples in medicine where helping one species directly helps another.